{"filing":{"accession_number":"0001104659-26-094848","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2622278d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_8k.htm"},"events":[{"id":27142,"run_id":24718,"accession_number":"0001104659-26-094848","anchor_item_number":"8.01","event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.94,"summary":"Outlook Therapeutics disclosed substantial doubt about its ability to continue as a going concern, citing a critical cash position of $11.2 million as of June 30, 2026 (and $7.7 million as of March 31, 2026) that is estimated to fund operations only into September 2026, along with substantial debt obligations.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28542,"accession_number":"0001104659-26-094848","item_number":"2.02","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Item 2.02 disclosure centers on preliminary cash position ($11.2 million as of June 30, 2026), but the accompanying risk factor exhibit (EX-99.1) contains explicit going-concern language: \"There is substantial doubt about our ability to continue as a going concern\" and states the company's cash \"will only be sufficient to fund our operations into September 2026.\" This is a material disclosure of substantial doubt about the registrant's ability to continue as a going concern, which is a terminal signal requiring immediate classification as such.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:04:59.217048+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28543,"accession_number":"0001104659-26-094848","item_number":"8.01","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure explicitly states \"There is substantial doubt about our ability to continue as a going concern\" and details the company's critical cash position (only $7.7 million as of March 31, 2026, estimated to fund operations only into September 2026) and substantial debt obligations. This is the unmistakable language of a going-concern disclosure, which is a terminal signal of existential risk to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:04:59.217048+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28542,"accession_number":"0001104659-26-094848","item_number":"2.02","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Item 2.02 disclosure centers on preliminary cash position ($11.2 million as of June 30, 2026), but the accompanying risk factor exhibit (EX-99.1) contains explicit going-concern language: \"There is substantial doubt about our ability to continue as a going concern\" and states the company's cash \"will only be sufficient to fund our operations into September 2026.\" This is a material disclosure of substantial doubt about the registrant's ability to continue as a going concern, which is a terminal signal requiring immediate classification as such.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:04:59.217048+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-12"},{"id":28543,"accession_number":"0001104659-26-094848","item_number":"8.01","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure explicitly states \"There is substantial doubt about our ability to continue as a going concern\" and details the company's critical cash position (only $7.7 million as of March 31, 2026, estimated to fund operations only into September 2026) and substantial debt obligations. This is the unmistakable language of a going-concern disclosure, which is a terminal signal of existential risk to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:04:59.217048+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-12"}]}